Larimar Therapeutics, Inc.
nomlabofusp
Friedreich’s ataxia
Resolved
7days ago
FDA decision · Jun 30, 2026
What's at stake
The FDA's approval decision on nomlabofusp for Friedreich’s ataxia is due Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved.”